Wall Street Zen Upgrades Ionis Pharmaceuticals (NASDAQ:IONS) to “Hold”

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other research firms have also issued reports on IONS. Weiss Ratings restated a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, October 15th. Barclays dropped their price target on shares of Ionis Pharmaceuticals from $90.00 to $85.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. TD Cowen cut their price target on shares of Ionis Pharmaceuticals from $84.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, November 10th. Royal Bank Of Canada reduced their price objective on shares of Ionis Pharmaceuticals from $85.00 to $60.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 10th. Finally, The Goldman Sachs Group reduced their price objective on shares of Ionis Pharmaceuticals from $58.00 to $41.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 10th. Nineteen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.71.

Get Our Latest Research Report on Ionis Pharmaceuticals

Ionis Pharmaceuticals Price Performance

Shares of IONS opened at $29.06 on Friday. The company has a market cap of $4.84 billion, a PE ratio of -8.75 and a beta of 0.43. The business has a fifty day moving average of $43.65 and a 200 day moving average of $64.57. Ionis Pharmaceuticals has a 52-week low of $27.25 and a 52-week high of $86.74. The company has a quick ratio of 5.36, a current ratio of 5.43 and a debt-to-equity ratio of 3.42.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.57. Ionis Pharmaceuticals had a negative net margin of 56.98% and a negative return on equity of 120.62%. The company had revenue of $242.72 million during the quarter, compared to analyst estimates of $178.17 million. During the same period in the previous year, the firm earned ($0.80) earnings per share. Ionis Pharmaceuticals’s quarterly revenue was up 54.8% compared to the same quarter last year. On average, sell-side analysts expect that Ionis Pharmaceuticals will post -3.57 EPS for the current year.

Insider Transactions at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Shannon Devers sold 1,357 shares of the firm’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the transaction, the executive vice president owned 17,811 shares of the company’s stock, valued at approximately $775,490.94. This trade represents a 7.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Hayden purchased 5,000 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 10th. The stock was acquired at an average price of $29.64 per share, with a total value of $148,200.00. Following the acquisition, the director owned 27,000 shares in the company, valued at approximately $800,280. This represents a 22.73% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 1.81% of the company’s stock.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Entropy Technologies LP raised its stake in Ionis Pharmaceuticals by 36.6% in the third quarter. Entropy Technologies LP now owns 50,303 shares of the company’s stock worth $2,246,000 after buying an additional 13,488 shares in the last quarter. Jump Financial LLC lifted its holdings in Ionis Pharmaceuticals by 54.0% during the third quarter. Jump Financial LLC now owns 471,682 shares of the company’s stock worth $21,061,000 after buying an additional 165,352 shares during the period. FORA Capital LLC lifted its holdings in Ionis Pharmaceuticals by 308.2% during the third quarter. FORA Capital LLC now owns 56,460 shares of the company’s stock worth $2,520,000 after buying an additional 42,627 shares during the period. Marshall Wace LLP boosted its position in Ionis Pharmaceuticals by 705.0% during the 3rd quarter. Marshall Wace LLP now owns 68,433 shares of the company’s stock valued at $3,056,000 after acquiring an additional 59,932 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its position in Ionis Pharmaceuticals by 0.4% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 132,399 shares of the company’s stock valued at $5,912,000 after acquiring an additional 581 shares in the last quarter. 93.86% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Ionis Pharmaceuticals

These are some of the IONS headlines that stood out recently:

  • Positive Sentiment: Two-year DAWNZERA data presented at the ACAAI meeting supported durable efficacy and disease control for hereditary angioedema, adding clinical evidence for the drug. Wells Fargo also rated Ionis a Buy. DAWNZERA long-term data Wells Fargo rating
  • Negative Sentiment: Ionis reportedly cut its full-year TRYNGOLZA sales outlook by roughly half after third-quarter sales reached just $9.3 million. The sales shortfall prompted investor-law-firm investigations, creating additional legal and reputational overhang. Investor investigation notice Wolf Popper investigation
  • Negative Sentiment: Several firms—including Morgan Stanley, Needham, HC Wainwright, Oppenheimer and Goldman Sachs—cut price expectations; a separate analyst downgrade was associated with a sharp recent decline in the shares. Artisan Partners also said its small-cap growth strategy exited Ionis following sequential Phase 3 setbacks. Morgan Stanley price target Artisan Partners exit

Ionis Pharmaceuticals Company Profile

(Get Free Report)

Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.

Further Reading

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.